Oskar Middel
Talks (0)
Exploring the role of big data analytics and dynamic capabilities in ESG programs within pharmaceuticals | Software Quality Journal
GMP & FDA Biologics Guidance | Thermo Fisher Scientific - USThermo Fisher Scientific LogoThermo Fisher Scientific LogoSearch buttonSearch buttonClosePlus IconMinus IconPlus IconMinus IconPlus IconMinus IconPlus IconMinus IconPlus IconMinus Icon
AI’s potential to accelerate drug discovery needs a reality checkClose bannerClose banner
TechBio Unicorn Owkin Teams Up with AWS to Advance Generative AI for Precision MedicineFacebookGoogle PlusInstagramMail ToLinkedInPinterestQuotation MarkTumblrTwitterYoutubeRSSmagnifygreater thanQuoteCloseSearchRight arrowIcon for read more (cta)Download I
Business Operations Lead, gCS Machine Learning for Drug Discovery (MLDD) in South San Francisco, California, United States of America | Business Strategy & Delivery at Genentech
Artificial Intelligence in Drug Discovery Market CAGR of 27.5%
Customer service vs. customer experience: Key differentiators
Enhancing Digital Performance through End-to-End Observability | by Sameer Paradkar | Oolooroo | Feb, 2024 | Medium
Mechanical and Manufacturing Engineering | BGSU
Scientist, Process Development | Norwood, Massachusetts | Moderna
Pitches (0)
add
Panels (1)
Oskar Middel

Add at least 3 tags
Your tags